These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3922294)

  • 1. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.
    Blaser J; Stone BB; Zinner SH
    Antimicrob Agents Chemother; 1985 Mar; 27(3):343-9. PubMed ID: 3922294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1054-60. PubMed ID: 3116917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1985 Jul; 28(1):64-8. PubMed ID: 3929682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection.
    Blaser J
    J Antimicrob Chemother; 1991 May; 27 Suppl C():21-8. PubMed ID: 1906863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.
    Daschner FD; Steffens A; Langmaack H
    Chemotherapy; 1979; 25(5):282-5. PubMed ID: 113178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compiled data on aminoglycoside, foremost netilmicin susceptibility of bacterial strains.
    Juhlin I; Tunevall G
    Scand J Infect Dis Suppl; 1980; Suppl 23():39-44. PubMed ID: 6782657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of netilmicin, gentamicin, and amikacin.
    Kantor RJ; Norden CW
    Antimicrob Agents Chemother; 1977 Jan; 11(1):126-31. PubMed ID: 402104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro study of netilmicin compared with other aminoglycosides.
    Fu KP; Neu HC
    Antimicrob Agents Chemother; 1976 Sep; 10(3):526-34. PubMed ID: 10829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of the synergism of piperacillin and netilmicin against blood culture isolates.
    Arpi M; Jørgensen PE; Pedersen HF
    Chemotherapy; 1986; 32(1):68-74. PubMed ID: 3081304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial resistance after in vitro exposure to amikacin and netilmicin.
    van de Klundert JA; Vliegenthart JS; Mouton RP
    Eur J Clin Microbiol; 1986 Aug; 5(4):456-8. PubMed ID: 3093226
    [No Abstract]   [Full Text] [Related]  

  • 13. Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa.
    Barry AL; Miller GH; Hare RS; Jones RN; Thornsberry C
    J Clin Microbiol; 1984 Mar; 19(3):311-4. PubMed ID: 6425354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Netilmicin: in vitro activity, time-kill evaluation and postantibiotic effect on microorganisms isolated from ocular infections.
    Bonfiglio G; Scuderi AC; Russo G
    Chemotherapy; 2001; 47(2):117-22. PubMed ID: 11173813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical comparative evaluation of aminoglycosides.
    Abbate GF; Alagia I; Giaquinto E; Giordano B; Leonessa V; Altucci P
    Chemioterapia; 1984 Dec; 3(6):378-84. PubMed ID: 6529780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones.
    Schlaeffer F; Blaser J; Laxon J; Zinner S
    J Antimicrob Chemother; 1990 Jun; 25(6):941-8. PubMed ID: 2115038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of netilmicin in newborn infants.
    Siegel JD; McCracken GH; Thomas ML; Threlkeld N
    Antimicrob Agents Chemother; 1979 Feb; 15(2):246-53. PubMed ID: 426516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects.
    Xiong YQ; Caillon J; Drugeon H; Potel G; Baron D
    Antimicrob Agents Chemother; 1996 Jan; 40(1):35-9. PubMed ID: 8787875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.
    Van der Auwera P; Klastersky J; Lieppe S; Husson M; Lauzon D; Lopez AP
    Antimicrob Agents Chemother; 1986 Feb; 29(2):230-4. PubMed ID: 3087276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Laboratory and clinical studies on T-1982 (cefbuperazone) in the field of pediatrics].
    Toyonaga Y; Kurosu Y; Koda N; Ida H; Mochizuki H; Kumagai K; Akatsuka J; Sugita M; Kawamura G; Okabe T; Hori M; Takahashi T
    Jpn J Antibiot; 1983 Apr; 36(4):739-70. PubMed ID: 6410101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.